VMW - VMware, Inc.

NYSE - NYSE Delayed Price. Currency in USD
+2.37 (+1.32%)
At close: 4:00PM EDT

184.41 +2.54 (1.40%)
Pre-Market: 9:23AM EDT

Stock chart is not supported by your current browser
Previous Close179.50
Bid181.64 x 800
Ask186.23 x 1000
Day's Range179.25 - 183.50
52 Week Range129.33 - 206.80
Avg. Volume1,245,028
Market Cap74.423B
Beta (3Y Monthly)0.92
PE Ratio (TTM)38.06
EPS (TTM)4.78
Earnings DateAug 21, 2019 - Aug 26, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date2018-12-31
1y Target Est193.77
Trade prices are not sourced from all markets
  • GuruFocus.com12 hours ago

    Vmware Inc (VMW) CEO Patrick P Gelsinger Sold $3.6 million of Shares

    CEO of Vmware Inc (30-Year Financial, Insider Trades) Patrick P Gelsinger (insider trades) sold 20,000 shares of VMW on 07/19/2019 at an average price of $180 a share. Continue reading...

  • VMware acquires ML acceleration startup Bitfusion
    TechCrunch5 days ago

    VMware acquires ML acceleration startup Bitfusion

    VMware today announced that it has acquired Bitfusion, a former participantin our Startup Battlefield competition

  • VMware Followers Could Find Its Shares Become Cheaper in the Weeks Ahead
    TheStreet.com7 days ago

    VMware Followers Could Find Its Shares Become Cheaper in the Weeks Ahead

    Traders and investors were disappointed recently when the IT company did not raise guidance and that weakness does not look like it has run its course.

  • Here's Why I Think VMware (NYSE:VMW) Might Deserve Your Attention Today
    Simply Wall St.8 days ago

    Here's Why I Think VMware (NYSE:VMW) Might Deserve Your Attention Today

    For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...

  • Palo Alto Ticks Twistlock on Buyout Checklist, Aids Portfolio
    Zacks13 days ago

    Palo Alto Ticks Twistlock on Buyout Checklist, Aids Portfolio

    Palo Alto's (PANW) acquisition of Twistlock will solidify its comprehensive cloud security strategy, Prisma, thereby providing better vigilance to the acquired entity's journey to the cloud.

  • Goldman-backed cloud firm Nasuni hires new marketing head
    American City Business Journals14 days ago

    Goldman-backed cloud firm Nasuni hires new marketing head

    Nasuni, a Goldman Sachs-backed cloud storage firm with a total funding of $145 million, hired VMware veteran David Grant to serve as its new chief marketing officer. Grant, who joins Nasuni after a one-year stint at Veeam Software, started the new job on June 24. At the time of his hire, the company did not have a CMO.  As a marketing executive at VMware for almost five years, Grant had to commute from Boston to the firm’s office in Palo Alto for almost three years.

  • GlobeNewswire15 days ago

    VMworld 2019 Returns to San Francisco and Barcelona to Help Attendees Learn, Connect and Innovate in the World of IT and Business

    VMware, Inc. (VMW), a leading innovator in enterprise software, today announced that VMworld 2019 US will be held Aug. 25-29 in San Francisco at the Moscone Center. Later this year, VMworld 2019 Europe will return to Fira Barcelona Gran Via from Nov. 4-7 in Barcelona. This year’s theme “Make Your Mark,” empowers VMworld 2019 attendees to learn, connect and innovate in the world of IT and business.

  • 5 Stocks With Over 20% Upside Potential, Say Top Analysts
    TipRanks16 days ago

    5 Stocks With Over 20% Upside Potential, Say Top Analysts

    The market is now at record levels. And according to Barclays, the rally isn’t going to stop anytime soon. The firm now sees a 65% chance the S&P 500 will surge 10% higher from current levels. “After the truce in the U.S.-China trade war post the G-20 meeting in Osaka, the ‘melt-up’ scenario ... is now our highest probability outcome,” says Maneesh Deshpande, head of equity derivatives strategy at Barclays.Deshpande adds that he believes two bullish catalysts will help push shares higher. First he is confident that the Fed will still embark on an easing cycle. “The weakness in global manufacturing continues unabated and the subdued inflation and softening inflation expectations will likely prompt some ‘insurance cuts’ from the Fed” says the analyst.At the same time “the current manufacturing weakness is unlikely to morph into a full recession given the resilience in the services sector of the economy,” says Deshpande.So with this bullish outlook in mind, which stocks are primed to swing higher? Here we turned to the Street to see which stocks analysts believe still have plenty of growth potential ahead. That’s according to the upside potential from the average analyst price target. Let’s see how that works out now: 1\. VMware (VMW)Software stock VMware virtualizes computing, from the data center to the cloud to mobile. For its customers, VMware can help lower IT costs, provide more flexibility, and offer more automated and resilient systems. Shares in the Dell (DELL) subsidiary are up 23% year-to-date, with the company delivering a robust first quarter despite not raising guidance.Most excitingly, VMware will now run on Microsoft’s (MSFT) Azure public cloud. The news, announced back in April, comes after a similar deal was struck with heavyweight Amazon's (AMZN) Amazon Web Services (AWS) three years ago. According to Wedbush analyst Daniel Ives, “VMW is looking to position itself as the key engine and virtualization platform; a clear catalyst for growth heading into FY20 and beyond in our opinion.” He has just reiterated his buy rating on the stock with a $210 price target (24% upside potential). “In a nutshell we remain very positive on VMware's technology and execution and believe it is uniquely well positioned to be a clear leader in enabling hybrid cloud deployments” writes Ives.Over the last three months, 13 analysts have published buy ratings on the stock vs 3 hold ratings. With an average price target of $215, analysts are looking for upside potential of 27%. View VMW Price Target & Analyst Ratings Detail 2\. Dicerna (DRNA)This biopharma has already soared over 38% year-to-date, but according to the Street sizable upside potential continues to lie ahead. In the last week, four analysts reiterated their buy ratings on Dicerna stock. That’s after the company unveiled its rare liver disease program for the treatment of alpha-1 antitrypsin (A1AT) deficiency (AATD).Analysts reacted positively to the announcement. “The choice of AATD as first entry into a rare, genetic liver disease makes a lot of sense on multiple levels” sums up HC Wainwright’s Ed Arce. For example, AATD is an indication with a significant unmet medical need (no approved therapies; severe cases can be life-threatening), while also presenting a rapid and efficient development path to approval.The analyst continues: “We view this as another key milestone, not just in further solidifying a track record of execution, but more importantly, in the long-term growth plan of a rapidly expanding and maturing company that we believe represents a core, pure-play holding in the greater nucleic acid therapy space.”Taking a step back we can see that his bullish tone is reflected by the Street. Seven analysts have published recent buy ratings on the stock, and their $22 average price target suggests impressive upside potential of 47%. View DRNA Price Target & Analyst Ratings Detail 3\. Columbia Sportswear (COLM)Five-star Guggenheim analyst Robert Drbul has just hosted meetings in Kansas City and Chicago with the COLM management team including CEO Tim Boyle and Director Andrew Burns. With a price target of $125, Drbul sees shares ripping 24% higher over the coming months. He is encouraged by ongoing strong momentum and sees footwear as a sizable opportunity for the company. That’s because right now it only represents about 22% of the company’s business today. And looking ahead, COLM’s goal is to double footwear in 3 to 5 years under the leadership of Peter Ruppe.“We continue to believe COLM is one of the more attractive growth names in our group, with significant long-term top-line growth and operating margin expansion opportunities, while the company continues to invest in demand creation in an effort to improve consumer demand” enthuses the analyst. Overall, 7 analysts have published buy ratings on the stock, with only 1 analyst staying on the sidelines. Meanwhile the average analyst price target of $121 indicates 20.5% upside potential from current levels. View COLM Price Target & Analyst Ratings Detail 4\. GW Pharma (GWPH)If you haven’t heard of GW Pharma before, this is one of the world’s most prominent cannabis companies. British-based GWPH developed the first ever cannabis plant-derived medicine to receive FDA approval. Called Epidiolex, the drug treats seizures associated with Lennox-Gastaut syndrome or Dravet Syndrome, two rare and severe drug-resistant epilepsy syndromes.So far the company’s Epidiolex launch has proved tremendously successful. For example, the drug’s first quarter sales of $33.5 million sailed past the expected figure of just $20.7 million. Top Piper Jaffray analyst Danielle Brill commented, "expectations for this launch have been sky high - and GWPH continues to deliver.” Brill is optimistic for the company’s outlook, writing: “We think the growth trajectory will continue over the coming quarters given expected EU launch, ongoing dose-titrations, increasing penetration into adult population, transition of remaining expanded access program patients to commercial product, and expansion into new indications." With this in mind, she reiterated her buy rating and $210 price target (22% upside potential). In fact this is slightly more conservative than the Street’s average analyst price target of $220 (28% upside potential). Ten analysts are covering the stock right now; all rate GWPH a ‘buy.’ View GWPH Price Target & Analyst Ratings Detail 5\. Alibaba (BABA)It’s all change over at Chinese e-commerce king Alibaba. The company recently announced that CFO Maggie Wu will replace Executive Vice Chair Joe Tsai as head of strategic acquisitions and investments. That’s as the company reorganizes several business divisions including DingTalk and Freshippo. Separately, in a recent 6-K filing, Alibaba proposed a one-for-eight stock split, to increase “flexibility in the company’s capital raising activities, including the issuance of new shares.”Following the news, top-rated Stifel Nicolaus analyst Scott Devitt reiterated his bullish outlook on the stock. “We recently added shares of BABA to the Stifel Select List and continue to recommend the idea for investors with long-term investment horizons” said the analyst.He approves of the recent developments at BABA. For, example, the analyst writes of Maggie Wu’s new appointment: “Wu has been CFO since 2013 and first joined Alibaba in 2007; we view her increased responsibilities at the top of the organization as a natural progression in the company’s leadership.”More importantly, he views the stock split proposal as a step towards a reported Hong Kong listing. Indeed, Alibaba recently filed confidential paperwork for a listing on the Hong Kong stock exchange with plans to raise as much as $20B, according to multiple news reports. “New capital could be deployed for buybacks or to extend the company’s competitive lead” contends Devitt. “Investors in mainland China, who can buy and sell Hong Kong-listed stocks through a cross-boundary trade link, could also stimulate demand for shares” the analyst added. In total the company has received 15 back-to-back buy ratings from the Street over the last three months. They are predicting (on average) 28% upside potential from current levels. View BABA Price Target & Analyst Ratings DetailGo to TipRanks' Stock Screener to find your own 'Strong Buy' stocks

  • The Zacks Analyst Blog Highlights: VMware, Schwab, HCA Healthcare, Cognizant and Hilton
    Zacks18 days ago

    The Zacks Analyst Blog Highlights: VMware, Schwab, HCA Healthcare, Cognizant and Hilton

    The Zacks Analyst Blog Highlights: VMware, Schwab, HCA Healthcare, Cognizant and Hilton

  • Top Research Reports for VMware, Schwab & HCA Healthcare
    Zacks20 days ago

    Top Research Reports for VMware, Schwab & HCA Healthcare

    Top Research Reports for VMware, Schwab & HCA Healthcare

  • Why Is VMware (VMW) Down 12.5% Since Last Earnings Report?
    Zacks24 days ago

    Why Is VMware (VMW) Down 12.5% Since Last Earnings Report?

    VMware (VMW) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Thomson Reuters StreetEvents25 days ago

    Edited Transcript of VMW earnings conference call or presentation 30-May-19 8:30pm GMT

    Q1 2020 VMware Inc Earnings Call

  • We're talking Kubernetes at TC Sessions: Enterprise with Google's Aparna Sinha and VMware's Craig McLuckie
    TechCrunch26 days ago

    We're talking Kubernetes at TC Sessions: Enterprise with Google's Aparna Sinha and VMware's Craig McLuckie

    Over the past five years, Kubernetes has grown from a project inside of Google to an open source powerhouse with an ecosystem of products and services, attracting billions of dollars in venture investment. On September 5th at TC Sessions: Enterprise, we're going to be discussing the rise of Kubernetes with two industry veterans. For starters we have Aparna Sinha, director of product management for Kubernetes and the newly announced Anthos product.

  • TheStreet.com26 days ago

    Dell Technologies and VMWare Risk Falling Further - Charts

    As the trade war lumbers on, some stocks are being held hostage, Jim Cramer told viewers of Mad Money last Friday. Cramer told viewers that he would be a buyer of Dell into any additional G-20 summit weakness this week. , the virtualization company where Dell owns a large stake.

  • 4 Cloud Stocks Besides Microsoft That Can Win
    Investopedia28 days ago

    4 Cloud Stocks Besides Microsoft That Can Win

    As the cloud-computing space continues to grow at exponential rates, a number of lesser known companies are set to outperform.

  • Investopedia28 days ago

    FanDuel Looking to Go Public in Reverse Merger

    Leading fantasy sports company FanDuel Inc. is in advanced talks to hit the public markets, yet probably not in the traditional sense with an initial public offering (IPO). Instead, the New York-based company is likely to to participate in a reverse merger with Platinum Eagle Acquisition Corp. (EAGLU), as first reported by Axios. Platinum Eagle is a special purpose acquisition company (SPAC), which are essentially management teams that raise money from the public markets with the intent of taking over one or a handful of companies.

  • What Should We Expect From VMware, Inc.'s (NYSE:VMW) Earnings In The Next 12 Months?
    Simply Wall St.last month

    What Should We Expect From VMware, Inc.'s (NYSE:VMW) Earnings In The Next 12 Months?

    Based on VMware, Inc.'s (NYSE:VMW) earnings update on 03 May 2019, the consensus outlook from analysts appear somewhat...

  • TheStreet.comlast month

    Dell Gains as Deutsche Bank Initiates Coverage With a Buy Rating

    rose on Thursday after Deutsche Bank re-initiated coverage on the company with a buy rating and a $62 one-year price target. Shares of the Round Rock, Texas-based company gained 1.82% tot $54.38 in mid-morning trading on the New York Stock Exchange after Deutsche Bank analyst Jeriel Ong initiated his own coverage of the company. VMware is a Dell Technologies portfolio company.

  • American City Business Journalslast month

    Here are Silicon Valley’s top 10 CEOs, as ranked by their employees

    It isn’t easy leading a major company in Silicon Valley, where the pressure to compete is intense, for both disruptive products and talent.
 Still, a number of Silicon Valley CEOs again rose to the top of this year’s list of top CEOs, as ranked by anonymous employee review site Glassdoor.

  • Barrons.comlast month

    Lagging Dell Stock Looks Like a Bargain

    After badly lagging the rest of the sector, Dell is now one of the cheapest large-cap tech stocks. One analyst says shares, trading at $51, could be worth $90.

  • GlobeNewswirelast month

    Global Organizations Accelerate their Cloud Journey with VMware

    VMware, Inc. (VMW), in conjunction with the 2019 VMware Cloud Briefing, today highlighted customers Bossa Studios, Rosendin Electric, Stagecoach, Trend Micro, and Zipwhip, and how they are addressing their hybrid cloud, multi-cloud and modern apps strategies with VMware Cloud on AWS, CloudHealth by VMware, VMware Secure State, and Wavefront by VMware.

  • The Funded: VMware buys Avi Networks; 12 Bay Area startups raise over $500M
    American City Business Journalslast month

    The Funded: VMware buys Avi Networks; 12 Bay Area startups raise over $500M

    Five acquisitions and a dozen funding deals that raised over $500 million top the Bay Area's venture news at the end of the week.

  • GlobeNewswirelast month

    VMware Announces Intent to Acquire Avi Networks

    VMware, Inc. (VMW), today announced its intent to acquire Avi Networks, a leader in multi-cloud application delivery services. Deployed today at hundreds of global enterprises—including Fortune 500 companies representing the world’s largest financial services, media, and technology companies—Avi Networks will further enable VMware to bring the public cloud experience to the entire data center—automated, highly scalable, and intrinsically more secure with the ability to deploy applications with a single click, upon close of the acquisition.

  • 5 minutes with… Joe Kinsella, vice president and CTO of CloudHealth
    American City Business Journalslast month

    5 minutes with… Joe Kinsella, vice president and CTO of CloudHealth

    CloudHealth founder Joe Kinsella recently spoke with the Business Journal's Lucia Maffei about how his role has evolved over the years, how CloudHealth was supposed to pursue an exit as a public company, and his passion for baseball.

  • Is VMware, Inc. (VMW) A Good Stock To Buy ?
    Insider Monkeylast month

    Is VMware, Inc. (VMW) A Good Stock To Buy ?

    Like everyone else, elite investors make mistakes. Some of their top consensus picks, such as Amazon, Facebook and Alibaba, have not done well in Q4 due to various reasons. Nevertheless, the data show elite investors' consensus picks have done well on average over the long-term. The top 20 stocks among hedge funds beat the S&P […]